Table 2.
piRNA | Cancer | Expression | Related gene | Mechanical points | Clinical Utility | Sample Type |
Detection Technique | Reference | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
TCGA | Tissue | cell | serum | mice | ||||||||
piR-651 | Breast cancer | ↑ | Estrogen and Androgen | Modulated by estrogen and androgen hormone levels | Theraputic | no | no | yes | no | no | RT-PCR | 114 |
↑ | – | – | Diagnostic | no | yes | yes | no | no | piRNA microarrayRT-PCR | 115 | ||
Cervical cancer | ↑ | – | – | Diagnostic | no | no | yes | no | no | piRNA microarrayRT-PCR | 115 | |
Gastric cancer | ↓ | – | The piR-651 level in gastric adenocarcinoma was higher than that in gastric signet ring cell carcinoma. | Diagnostic Theraputic |
no | no | no | yes | no | RT-PCR | 116 | |
↑ | – | Promote cancer cell growth | Diagnostic | no | no | yes | no | no | piRNA microarrayRT-PCR | 115 | ||
Hodgkin lymphoma | ↓ | – | – | Diagnostic | no | yes | yes | yes | no | RT-PCR | 117 | |
Liver cancer | ↑ | – | – | Diagnostic | no | no | yes | no | no | piRNA microarrayRT-PCR | 115 | |
Lung cancer | ↑ | Caspase-3-p17, cleaved-PARP-1, Bcl-2 | piR651 inhibitor induced cell apoptosis, with caspase-3-p17 and cleaved-PARP-1 increased, whereas Bcl-2 expression decreased | Diagnostic | no | no | yes | no | no | RT-PCR | 118 | |
↑ | – | – | Diagnostic | no | no | yes | no | no | piRNA microarrayRT-PCR | 115 | ||
↑ | Cyclin D1 and CDK4 | piR-651 induces NSCLC progression through the cyclin D1 and CDK4 pathway | Diagnostic Theraputic |
no | yes | yes | no | yes | RT-PCR | 119 | ||
↑ | – | promote cell proliferation, apoptosis, migration and invasion | Theraputic | no | no | yes | no | no | RT-PCR | 120 | ||
Mesothelium | ↑ | – | – | Diagnostic | no | no | yes | no | no | piRNA microarrayRT-PCR | 115 | |
Prostate cancer | ↑ | Estrogen and Androgen | Modulated by estrogen and androgen hormone levels | Theraputic | no | no | yes | no | no | RT-PCR | 114 | |
piR-823 | Breast cancer | ↑ | Estrogen and Androgen | Modulated by estrogen and androgen hormone levels | Theraputic | no | no | yes | no | no | RT-PCR | 114 |
Colorectal cancer | ↑ | HSF1 (heat shock protein (HSP) 27, 60, 70) | Upregulate phosphorylation and transcriptional activity of HSF1 | Theraputic | no | yes | yes | no | no | RT-PCR | 121 | |
Gastric cancer | ↓ | – | The piR-823 level was positively associated with tumor-node-metastasis stage and distant metastasis. | Diagnostic Theraputic |
no | no | no | yes | no | RT-PCR | 116 | |
↓ | – | Inhibited cell growth in vitro and in vivo. | Theraputic | no | yes | yes | no | yes | piRNA microarray RT-PCR | 122 | ||
Kidney cancer | ↑/↓ | – | piR-823 is down-regulated in tumor tissue, but positively correlated with worse outcome, indicating its complex role in RCC pathogenesis (↑blood serum and urine↓tumor tissue) | Diagnostic | no | yes | no | yes | no | RT-PCR | 123 | |
Liver cancer | ↑ | Gradually increased from cirrhosis to low- and high-grade dysplastic nodules and to hepatocellular carcinoma (HCC) | Diagnostic | no | no | yes | no | no | RT-PCR | 55 | ||
Multiple myeloma | ↑ | VEGF, IL-6, ICAM-1, CXCR4, Bax, Bcl2 | Promoted cell proliferation, tube formation, and invasion by enhancing VEGF, IL-6, ICAM-1, CXCR4 and attenuating apoptosis. (inhibition of Caspase-3 activation, downregulation of Bax, and upregulation of Bcl2) and production of ROS and NO | Prognostic Therapeutic | no | no | yes | yes | yes | RT-PCR | 20 | |
↑ | DNMT3B | Myeloid-derived suppressor cells confer stem-like qualities to multiple myeloma cells by upregulating piRNA-823 expression and activating DNMT3B activation | Theraputic | no | yes | yes | no | yes | RT-PCR | 83 | ||
↑ | DNMT3A and 3B, p16INK4A | induce de novo DNA methyltransferases, DNMT3A and 3B and inhibit methylation-silenced tumor suppressor, p16INK4A. |
Theraputic | no | yes | yes | no | no | RT-PCR | 124 | ||
Prostate cancer | ↑ | Estrogen and Androgen | Modulated by estrogen and androgen hormone levels | Theraputic | no | no | yes | no | no | RT-PCR | 114 | |
piR-4987 | Breast cancer | ↑ | – | Up-regulated piR-4987 expression was associated with lymph node positivity | Prognostic | no | yes | no | no | no | piRNA microarray RT-PCR | 88 |
Multiple myeloma | ↑ | – | Upregulated in stage III MM patients compared with healthy individuals | Diagnostic | no | yes | no | no | no | RT-PCR | 124 | |
piR-Hep1 | Liver cancer | ↑ | AKT | Promotes cell viability, motility, and invasiveness by activation of AKT phosphorylation | – | no | yes | yes | no | no | RT-PCR | 97 |
Multiple myeloma | ↑ | – | Upregulated in stage III MM patients compared with healthy individuals | Diagnostic | no | yes | no | no | no | RT-PCR | 124 | |
piR-39980 | Fibrosarcoma | ↓ | RRM2 | piR-39980 promotes apoptosis and inhibits proliferation by repressing RRM2 through direct targeting at its 3′-UTR through extensive sequence complementary binding | Therapeutic | no | no | yes | no | no | RT-PCR | 108 |
Neuroblastoma | ↑ | JAK3 | Inhibition of piRNA induces NB cells senescence by modulating JAK3 through target binding. piR-39980 desensitizes the effect of doxorubicin and inhibit drug-induced apoptosis. | Theraputic | no | no | yes | no | no | piRNA profiling RT-PCR | 127 |
Abbreviation: BCL2, BCL2 apoptosis regulator; CDK4, Cyclin dependent kinase 4; CXCR4, C-X-C motif chemokine receptor 4; DNMT, DNA methyltransferase; JAK3, Janus kinase 3; HSP, heat shock protein; HSF1, heat shock transcription factor 1; VEGF, vascular endothelial growth factor; IL6, interleukin 6; ICAM1, intercellular adhesion molecule 1; MM, Multiple myeloma; RRM2, ribonucleotide reductase regulatory subunit M2; RT-PCR, quantificational real time-polymerase chain reaction; TCGA, The Cancer Genome Atlas; UTR, untranslated region.